


CLAIMS

1. A complex of eletriptan and a cyclodextrin derivative of formula (I):-

5



wherein

$R^{1a-g}$ ,  $R^{2a-g}$  and  $R^{3a-g}$  each independently represent -OH or -

10  $O(CH_2)_4SO_3H$ ; provided that at least one of  $R^{1a-g}$  represents  $-O(CH_2)_4SO_3H$ : or a pharmaceutically acceptable salt thereof.

2. A complex according to claim 1, wherein the average number of -  
 15  $O(CH_2)_4SO_3H$  groups per molecule of the derivative of the formula (I) is in the range of from 6.1 to 6.9.

3. A complex according to claim 1 wherein each  $-O(CH_2)_4SO_3H$  group present in the derivative of the formula (I) is in the form of an alkali metal salt.

20 4. A complex according to claim 1 wherein the molar ratio of eletriptan:cyclodextrin derivative of the formula (I) is from 1:1 to 15:1.

5. A complex according to claim 4 wherein the molar ratio of  
eletriptan:cyclodextrin derivative of the formula (I) is from 1:1 to 10:1.
6. A complex according to claim 1 wherein eletriptan is present in the form  
5 of the hemisulphate salt.
7. A pharmaceutical formulation including a complex according to claim 1  
and a pharmaceutically acceptable excipient, diluent or carrier.
- 10 8. A formulation according to claim 7 wherein from 50 to 120 mg/g of  
eletriptan hemisulphate is present.
9. A formulation according to claim 7 wherein from 15 to 25% weight/weight  
of the sulphobutylether-beta-cyclodextrin is present.
- 15 10. A formulation according to claim 7, including one or more of an anti-  
oxidant, a co-solvent and an organic polymer.
11. A formulation according to claim 10 wherein the anti-oxidant is ascorbic  
20 acid.
12. A formulation according to claim 11 wherein from 0.25 to 0.80%  
weight/weight of ascorbic acid is present.
- 25 13. A formulation according to claim 10 wherein the co-solvent is glycerol.
14. A formulation according to claim 13 wherein from 10.0 to 25.0%  
weight/weight of glycerol is present.
- 30 15. A formulation according to claim 10 wherein the organic polymer is  
carboxymethylcellulose or polyvinylpyrrolidone.

16. A formulation according to claim 15 wherein from 0.05 to 0.20% weight/weight of carboxymethylcellulose or polyvinylpyrrolidone is present.
17. A formulation according to claim 7 that is in the form of an aqueous solution.
18. An aqueous formulation according to claim 17 that has a pH of from 4.0 to 5.0.
19. A formulation according to claim 7 which is adapted for parenteral administration.
20. A formulation according to claim 7 which is adapted for intranasal administration.
21. A formulation according to claim 7 which is adapted for inhalation.
22. A formulation according to claim 7 that is an aqueous solution comprising:
- 80mg/g of eletriptan hemisulphate;
- 20% weight/weight of the sulphobutylether-beta-cyclodextrin derivative of formula (I) having an average sulphobutylether substitution of 6.5 per cyclodextrin molecule with each sulphobutylether unit present as its sodium salt;
- 20% weight/weight of glycerol; and
- 0.7% weight/weight of ascorbic acid:
- with the formulation having been adjusted to from pH 4.0 to 5.0, preferably about pH 4.5, using aqueous sodium hydroxide solution.
23. A formulation according to claim 7 that is an aqueous solution comprising:
- 80 mg/g of eletriptan hemisulphate;

20% weight/weight of the sulphobutylether-beta-cyclodextrin derivative of formula (I) having an average sulphobutylether substitution of 6.5 per cyclodextrin molecule with each sulphobutylether unit present as its sodium salt;

- 5           0.10% weight/weight of polyvinylpyrrolidone; and  
          0.7% weight /weight ascorbic acid:

with the composition having been adjusted to from pH 4.0 to 5.0, preferably about pH 4.5, using aqueous sodium hydroxide solution.

- 10   24.    A method of treating in a mammal a disease for which a  $5H_{1B/1D}$  receptor agonist is indicated including treating said mammal with an effective amount of a complex according to claim 1.

25.    A method of treating in a mammal migraine or preventing migraine  
15   recurrence in a mammal including treating said mammal with an effective amount of a complex according to claim 1.

26.    A process for the preparation of a complex according to claim 1 which comprises combining eletriptan, or a pharmaceutically acceptable salt thereof,  
20   with the cyclodextrin derivative, or a pharmaceutically acceptable salt thereof.

27.    A process for the preparation of a formulation according to claim 7 which comprises combining either (i) the complex comprising eletriptan and the cyclodextrin derivative of formula (I), or (ii) eletriptan, or a pharmaceutically  
25   acceptable salt thereof, and the cyclodextrin derivative, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable excipient, diluent or carrier.